Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 29.4% during mid-day trading on Friday . The company traded as high as C$0.11 and last traded at C$0.11. 602,760 shares were traded during mid-day trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Up 29.4%
The stock has a market capitalization of C$20.73 million, a price-to-earnings ratio of -4.07 and a beta of 1.25. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a 50 day moving average price of C$0.09 and a 200 day moving average price of C$0.10.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- URGENT: Trump Just Triggered AI’s Biggest Disruption Yet
- Wall Street Alert: Buy AES
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
